Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 9/20 | 0.48 |
| ▸ | ULK1 | O75385 | 6/20 | 0.46 |
| ▸ | ULK2 | Q8IYT8 | 2/20 | 0.46 |
| ▸ | FLT3 | P36888 | 6/20 | 0.45 |
| ▸ | KIT | P10721 | 2/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | BMX | P51813 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.42 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3496244 | 0.89 | PRKCQ (0.50) | AURKA | |
| SCHEMBL3496180 | 0.88 | JAK1 (0.47) | FLT3AURKAIGF1RJAK3ALK | |
| SCHEMBL3495590 | 0.88 | AURKA (0.41) | FLT3AURKACDK1IGF1RCDK2 | |
| SCHEMBL3496313 | 0.80 | ULK1 (0.49) | CHEK1ULK1ULK2FLT3KIT | |
| SCHEMBL3494720 | 0.80 | ULK1 (0.49) | CHEK1ULK1ULK2FLT3KIT | |
| SCHEMBL3496481 | 0.80 | ULK1 (0.46) | CHEK1ULK1ULK2FLT3KIT | |
| SCHEMBL3496131 | 0.79 | ULK1 (0.45) | CHEK1ULK1ULK2FLT3KIT | |
| SCHEMBL3496433 | 0.79 | ULK1 (0.49) | CHEK1ULK1ULK2 | |
| SCHEMBL3495452 | 0.79 | ULK1 (0.49) | CHEK1ULK1ULK2FLT3KIT | |
| SCHEMBL3497975 | 0.77 | SYK (0.61) | AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | claimed |
| US-8993585-B2 | Cyclic amine substituted pyrimidinediamines as PKC inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | PRKCH, PKD2, PRKCQ | CHEK1 184/4885ULK1 832/4885ULK2 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.